Evidence map›Paper›PMID 33161592›Full record

ArticleBritish journal of haematology2021

Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.

Anne E Bras, Zgjim Osmani, Valerie de Haas, Mojca Jongen-Lavrencic, Jeroen G Te Marvelde, C Michel Zwaan, Ester Mejstrikova, Paula Fernandez, Tomasz Szczepanski, Alberto Orfao and 2 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Clinical case reports · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. A novel immune prognostic model of non-M3 acute myeloid leukemia.American journal of translational research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Anne E BrasLaboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0001-5094-7700
Zgjim OsmaniLaboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Valerie de HaasDutch Childhood Oncology Group, Utrecht, the Netherlands.
Mojca Jongen-LavrencicDepartment of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jeroen G Te MarveldeLaboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
C Michel ZwaanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Ester MejstrikovaCLIP-Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic.
Paula FernandezInstitute for Laboratory Medicine, Kantonsspital Aarau AG, Aarau, Switzerland.
Tomasz SzczepanskiDepartment of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia (SUM), Katowice, Poland.
Alberto OrfaoCancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0002-0007-7230
Jacques J M van DongenDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Vincent H J van der VeldenLaboratory Medical Immunology (LMI), Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0001-9457-3763
Erasmus MC · NLCharles University · CZKantonsspital Aarau · CHLeiden University Medical Center · NLMedical University of Silesia · PLStichting Kinderoncologie Nederland · NLUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

Indexed as

LeukemiaNeoplasm ProteinsPeroxidaseAcute DiseaseFemaleFlow CytometryHumansImmunophenotypingMaleMPO protein, humanNeoplasm ProteinsPeroxidaseacute leukaemiaALLAMLflow cytometryimmunophenotypingmyeloperoxidase

Identifiers

PMID33161592
PMCPMC8247412
OpenAlexW3104441174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.